logo

VIROPHARMA(NSDQ:VPHM)
VIROPHARMA is a leader in RNA virology and RNA antiviral drug discovery and development. The company is committed to the commercialization, development and discovery of antiviral pharmaceuticals. The company focuses on drug development and discovery activities for viral diseases including viral meningitis, viral respiratory infection, pneumonia, hepatitis C and influenza. Each year, a majority of the world''s population is afflicted by at least one of these diseases, and antiviral therapies are either inadequate or do not exist.
# Employees: 201
Address: 397 Eagleview Boulevard,Exton,PA,USA
Phone: 610 458-7300
Fax: 610 458-7380
Website: www.viropharma.com
Email:
Sector: Medical
Industry: MED-DRUGS
Executive Officers
Michel de Rosen (Chmn.; Presi.; C.E.O.; Dir.)
Vincent J. Milano (V.P.; C.F.O.; C.O.O.; Treas.)
Daniel B. Soland (V.P.; Chief Commercial Off.)
Colin Broom M.D. (V.P.; Chief Scientific Off.)
Thomas F. Doyle (V.P.; Gen. Counl. & Sec.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2009
Next Earnings Date(Expected): 2/23/2010
Mean EPS (Next Qtr): $0.21
Mean EPS (Year): ($0.09)
Mean Estimate(Long Term): $16.60
P/E Ratio(Based on EPS estimate): -0.010
Number of Estimates: 9
Shares Performance
Period VPHM Compare to S&P
YTD -40.86 % -51.06 %
4 Weeks -17.65 % -18.54 %
12 Weeks -5.17 % -10.60 %
Shares Information
Analyst Coverage: Y
Avg Volume: 1338648
Shares Outstanding: 77M
Market Cap: $0.60B
52 Week High: $14.15
52 Week Low: $3.98
P/E Ratio: 11.850
PEG Ratio: -0.010
Split: On 1/1/1990 VPHM split by factor of 1.500
Earnings Performance
EPS Growth in Last Quarter: 70.00 %
EPS Growth in Last Year: 3.03 %
Sales Growth in Last Quarter: -1.61 %
Sales Growth in Last Quarter: 22.21 %
Financials
Qtr Book Value: $0.81
Cash Flow/Share: $7.40
Change in Payout Ratio: 0.000
Price/Sales: 2.190
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia